Compare Novo Nordisk A/S (NVO) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Sezzle Inc — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Sezzle Inc trades at $128.64 (market cap $3.95B). The key difference: Novo Nordisk A/S is far larger — about 41.9× Sezzle Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Sezzle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Sezzle Inc for 15 Days on average.
| NVO | SEZL | |
|---|---|---|
Market Cap | $165.31B | $3.95B |
Volume | 11,432,838 | 550,075 |
Sector | Health | Financials |
52-Week High | $63.98 | $188.55 |
52-Week Low | $35.29 | $50.97 |
Typical Hold Time | 116 Days | 15 Days |
Enterprise Value | $179.56B | $3.99B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
SEZL stock is trading at $128.64, up 12.99% in the past 24 hours, showing strong momentum with a bullish technical signal. The company demonstrates exceptional profitability with 72.36% gross margins and 30.35% net income margins, while recent earnings have consistently beaten expectations. Analyst consensus remains strongly positive with a $168 price target representing significant upside potential from current levels.
SEZL presents a compelling growth opportunity with robust financial metrics and strong analyst support, though investors should monitor competitive pressures in the BNPL sector and the stock's current technical overbought conditions. The company's expanding product portfolio and subscriber growth provide fundamental support for continued appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
